Базисный препарат для терапии хронической обструктивной болезни легких

1. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. The 2009 report is available on: www.goldcopd.com
2. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–50.
3. Чучалин А.Г., Овчаренко С.И., Лещенко И.В., Белевский А.С. Определение, классификация и диагностика ХОБЛ. Клинические рекомендации. Хроническая обструктивная болезнь легких. Под ред. А.Г.Чучалина. М.: Атмосфера, 2007; с. 8–22.
4. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46.
5. Panning CA, DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003; 23: 183–9.
6. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med 2010; 16: 97–105.
7. Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.
8. Celli B, Wallack RZ, Wang S et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–8.
9. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009; 34: 757–69.
10. Bauwens O, Ninane V, Van de Maele B et al. 24-hour bronchodilator efficacy of single doses indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009; 25: 463–70.
11. Beier J, Beeh KM, Brookman L et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009; 22 (6): 492–6.
12. Fogarty C, Worth H, Hebert J et al. Sustained 24-h bronchodilation with indacaterol once-daily in COPD: a 26-week efficacy and safety study. Am J Respir Crit Care Med 2009; 179: A4547.
13. Magnussen H, Paggiaro P, Jack D et al. Bronchodilatador treatment with indacaterol once-daily vs formoterol twice-daily in COPD: a 52-week study. Am J Respir Crit Care Med 2009; 179: A6184.
14. Nonikov V, Verkindre C, Jack D et al. B. Indacaterol once-daily reduces days of poor control in COPD over 52 weeks of treatment. Am J Respir Crit Care Med 2009; 179: A6190.
15. Magnussen H, Paggiaro P, Jack D et al. Indacaterol once-daily improves health-related quality of life in COPD patients: a 52-week study versus placebo and formoterol. Eur Respir J 2009; 53s: P2019.
16. Buhl R, Pieters W, Jack D et al. Indacaterol once-daily improves dyspnoea and BODE index in COPD patients: a 52- week study versus twice-daily formoterol. Eur Respir J 2009; 53s: P2026
17. Buhl R, Pieters W, Jack D et al. Indacaterol once-daily reduces COPD exacerbations over 52 weeks of treatment. Am J Respir Crit Care Med 2009; 179: A6185.
18. Worth H, Kleerup E, Iqbal A et al. Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study. Eur Respir J 2009; 53s: P2030.
19. Chung F, Kornmann O, Jack D et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD. Eur Respir J 2009; 53s: E4359.
20. Fletcher CM. Elmes PC, Wood CH. The significance of respiratory symptoms and the diagnosis of chromic bronchitis in a working population. BMJ 1959; 1: 257–66.
21. Kohansal R, Martinez-Camblor P, Agustí A et al. The Natural History of Chronic Airflow Obstruction Revisited: An Analysis of the Framingham Offspring CohortAm J Respir Crit Care Med 2009; 180: 3–10.
22. Decramer M, Celli B, Tashkin DP et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the Uplift trial. COPD 2004; 1: 303–12.
23. Scanlon PD, Connett JE, Waller LA et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381–90.
24. Anthonisen NR, Skeans MA, Wise RA et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233–9.
25. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
26. Vincken W, van Noord JA, Greefhorst APM et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J 2002; 19: 209–16.
27. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18: 75–81.
28. Pauwels RA, Lofdahl CG, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948–53.
29. Vestbo J, Sorensen T, Lange P et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819–23.
30. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902–9.
31. Burge PS, Calverley PMA, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–303.
32. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365: 1552–60.
33. Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of COPD: a randomised controlled trial. Lancet 2003; 361 (9356): 449–56.
34. Decramer M, Celli B, Kesten S et al. for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–8.
35. Troosters T, Celli B, Lystig T et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010; 36: 65–73.
36. Morice AH, Celli B, Kesten S et al. COPD in young patients: A pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010; 104: 1659–67.
37. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269–76.
38. Mannino DM, Homa DM, Akinbami LJ et al. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill Summ 2002; 51: 1–16.
39. World Health Organization. Global initiative for chronic obstructive lung disease. Geneva (Switzerland): World Health Organization; 2002.
40. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; i: 681–6.
41. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391–8.
42. Anthonisen NR, Skeans MA,Wise RA et al. The effects of a smo-king cessation intervention on 14,5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233–9.
43. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059–73.
44. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ 2003; 326: 185–9.
45. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: Anticholinergics, but not b-agonists, Reduce Severe Exacerbations and Respiratory Mortality in COPD. J Gen Intern Med 2006; 21: 1011–9.
46. De Luise C, Lanes SF, Jacobsen J et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007; 22: 267–72.
47. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003; 22: 809–14.
48. Camilli AE, Robbins DR, Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991; 133: 795–800.
49. Engstrom G, Wollmer P, Hedblad B et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from “men born in 1914”, Malmo, Sweden. Circulation 2001; 103: 3086–91.
50. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 2640–6.
51. Viegas CA, Ferrer A, Montserrat JM. Ventilation-perfusion response after fenoterol in hypoxemic patients with stable COPD. Chest 1996; 110: 71–7.
52. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 2008; 300: 1439–50.
53. Celli B, Decramer M, Leimer I et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137; 20–30.
54. Reilly JJ. COPD and Declining FEV1 – Time to Divide and Conquer? N Engl J Med 2008; 359: 1616–8.
55. Burrows B, Fletcher CM, Heard BE et al. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet 1966; 87: 830–5.
56. Garcia-Aymerich J, Agusti А, Barberа JA et al. Phenotypic Heterogeneity of Chronic Obstructive Pulmonary Disease. Arch Bronconeumol 2009; 45: 133–42.
57. Han MK, Agusti A, Calverley PM et al. COPD phenotypes: The future of COPD. Am J Respir Crit Care Med 2010; 182: 598–604.
58. Lee J-H, Lee YK, Kim E-K et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010; 104: 542–9.
59. Gelb AF, Taylor CF, Cassino C et al. Tiotropium induced bronchodilation and protection from dynamic hyperinflation is independent of extent of emphysema in COPD. Pulm Pharmacol Ther 2009; 22: 237–42.
60. Tashkin DP, Celli B, Kesten S et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2010; 35: 287–94.
61. Tashkin DP, Celli B, Kesten S et al. Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT trial. Respir Med 2010; 104: 1495–504.

С.Н.Авдеев 

ФГУ НИИ пульмонологии ФМБА России, Москва